thrombogenic

(redirected from Thrombogenicity)
Also found in: Wikipedia.

throm·bo·gen·ic

(throm'bō-jen'ik),
1. Relating to thrombogen.
2. Causing thrombosis or coagulation of the blood.

thrombogenic

(thrŏm′bə-jĕn′ĭk)
adj.
Causing or resulting in thrombosis or coagulation of the blood.

throm·bo·gen·ic

(throm'bō-jen'ik)
1. Relating to thrombogen.
2. Causing thrombosis or coagulation of the blood.
References in periodicals archive ?
Heparin coating has been introduced into some PACs and has reduced the thrombogenicity, but has been associated with an increased incidence of heparin-induced thrombocytopenia (76).
Pulmonary inflammation and thrombogenicity caused by diesel particles in hamsters: role of histamine.
The risk of thrombogenicity has been reported in patients with hemophilia who receive PCC, (22) but studies of PCC use in warfarin reversal have not shown this adverse effect.
However, their thrombogenicity and low compliance inevitably lead to their occlusion.
The range of effects of potential biological hazards is wide and can include short-term effects, such as acute systemic toxicity, irritation, hemolysis, and thrombogenicity, as well as long-term effects, such as chronic toxicity, sensitization, genotoxicity, carcinogenicity and teratogenicity.
Our HAp coating had previously successfully completed a critical thrombogenicity animal trial where it was exposed to blood-flow and showed no signs of toxicity or thrombosis (blood- clotting).
Current evidence indicates that high intake of SFA and trans-fatty acids (TFA) may increase serum total and low density lipoprotein (LDL) cholesterol levels, reduce insulin sensitivity, enhance thrombogenicity and increase cardiovascular risk.
Auger et al., "Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: role of the Ang II/AT1 receptor/NADPH oxidase-mediated activation of MAPKs and PI3-kinase pathways," Circulation, vol.
Second, a correlation between the blood thrombogenicity and severity of calcification has been reported.
Thromboresistance Comparison of the HeartMate II Ventricular Assist Device With the Device Thrombogenicity Emulation-Optimized HeartAssist 5 VAD.
Atherogenecity index (AI) and thrombogenicity index (TI) were calculated using equations proposed by Ulbricht and Southgate (1991):